{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-035245","form_type":"8-K","ticker":"VTAK","cik":"0001716621","company_name":"Catheter Precision, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.242515+00:00","generated_at":"2026-05-16T19:52:57.716113+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Catheter Precision Q3 revenue up 135% to $226K; net loss down 45% to $2.25M","bullets":["Total revenue Q3 2025: $226K, +135% YoY from $96K; nine-month revenue $581K, +114%.","GAAP net loss Q3 2025: $2.25M, 45% reduction from $4.12M in Q3 2024.","Nine-month net loss $11.4M vs $11.0M; non-cash charges $4.2M.","CE Mark approval for LockeT driving international interest; reorders in South Africa and first French VIVO order.","VIVO clinical studies completed in 2025; CEO expects major US and international expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-035245","json":"https://secwatch.observer/filing/0001437749-25-035245.json","markdown":"https://secwatch.observer/filing/0001437749-25-035245.md","text":"https://secwatch.observer/filing/0001437749-25-035245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716621/000143774925035245/0001437749-25-035245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716621/000143774925035245/vtak20251113_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:52:57.716113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}